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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Farsi language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 102 JIA patients (14.7% systemic JIA, 67.6% oligoarticular, 15.7% RF negative polyarthritis, 
2.0% other categories) and 198 healthy children, were enrolled in three paediatric rheumatology centres. Notably, none of 
the enrolled JIA patients is affected with enthesitis-related arthritis or undifferentiated arthritis. The JAMAR components 
discriminated healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. 
In conclusion, the Farsi version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Farsi parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Farsi language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2012 to 
November 2012. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of 
the illness (yes/no) [15]. The JAMAR is available in 
three versions, one for parent proxy-report (child’s age 
2–18), one for child self-report, with the suggested age 
range of 7–18 years, and one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correlations 
(Pearson r: all items within a scale should contribute equally to 
the total score); third Likert assumption (item internal consist-
ency or linearity for which each item of a scale should be lin-
early related to the total score that is 90% of the items should 
have Pearson r ≥ 0.4); floor/ceiling effects (frequency of items 
at lower and higher extremes of the scales, respectively); inter-
nal consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be lower 
than their reliability coefficients, as measured by Cronbach’s 
alpha); test–retest reliability or intraclass correlation coef-
ficient (reproducibility of the JAMAR repeated after 1 or 2 
weeks); and construct validity in its two components: the con-
vergent or external validity which examines the correlation of 
the JAMAR subscales with the six JIA core set variables, with 
the addition of the parent assessment of disease activity and 
pain by the Spearman’s correlation coefficients (r) [17] and 
the discriminant validity, which assesses whether the JAMAR 
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discriminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with first and 
third quartiles and categorical data as absolute frequencies and 
percentages.
The complete Farsi parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Farsi JAMAR was fully cross-culturally adapted with two 
forward and two backward translations. The concordance rate 
between the original standard English version of the JAMAR 
and the 2 back translations was 94.5% (115/123 lines) for the 
parent version and 97.5% (117/120 lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines in the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%).
Demographic and clinical characteristics 
of the subjects
A total of 102 JIA patients and 198 healthy children (total 
of 300 subjects) were enrolled at three paediatric rheumatol-
ogy centres.
In the 102 JIA subjects, the JIA categories were 14.7% 
with systemic JIA, 67.6% with oligoarthritis, 15.7% with 
RF negative polyarthritis, 1.0% with RF positive polyar-
thritis and 1.0% with psoriatic arthritis. Notably, none of 
the enrolled JIA patients is affected with enthesitis-related 
arthritis or undifferentiated arthritis (Table 1).
A total of 199/300 (66.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (102 from par-
ents of JIA patients and 97 from parents of healthy chil-
dren). The JAMAR was completed by 154/199 (77.4%) 
mothers and 45/199 (22.6%) fathers. The child version of 
the JAMAR was completed by 133/300 (44.3%) children 
age 7.6 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did 
not allow to skip answers and input of null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 8 and 9, whereas a reduced 
number of response choices was used for all the PF items 
except for items 1, 3 and 4. The mean and SD of the items 
within a scale were roughly equivalent for the PF and for 
the HRQoL items, except for the HRQoL item 7 (data not 
shown). The median number of items marked as not appli-
cable was 0% (0–0%) for the PF and 1% (0–1%) for the 
HRQoL.
Floor and ceiling effect
The median floor effect was 89.2% (86.3–90.2%) for the 
PF items, 62.7% (56.9–79.4%) for the HRQoL PhH items, 
and 86.3% (72.5–92.2%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0.0%) for the PF items, 3.9% 
(2.9–4.9%) for the HRQoL PhH items, and 1.0% (0–2.0%) for 
the HRQoL PsH items. The median floor effect was 58.8% for 
the pain VAS, 10.8% for the disease activity VAS and 11.8% 
for the well-being VAS. The median ceiling effect was 0.0% 
for the pain VAS, 0.0% for the disease activity VAS and 0.0% 
for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
PF items, with the exception of PF item 15, and for 100% of 
the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 100% of 
items of the PF and 90% of items of the HRQoL (with the 
exception of HRQoL item 8).
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Table 1  Descriptive statistics (medians, 1st and 3rd quartiles or absolute frequencies and %) for the 102 JIA patients
Data related to the JAMAR refers to the 102 JIA patients and to the 97 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy subjects. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF- Polyarthritis RF + Polyarthritis Psoriatic Arthritis All JIA patients Healthy
N = 15 N = 69 N = 16 N = 1 N = 1 N = 102 N = 198
Female 8 (53.3%) 49 (71%) 11 (68.8%) 1 (100%) 1 (100%) 70 (68.6%) 104 (52.5%)*
Age at visit 6.3 (5.8–11) 7.8 (4.9–12) 8.6 (5.7–14.1) 16.8 (16.8–16.8) 13 (13–13) 7.9 (5.3–12.5) 10.5 (9.6–11.8)#
Age at onset 4.6 (3.1–6.3) 5.1 (2.3–7.3) 5.7 (2.9–8.1) 8.3 (8.3–8.3) 6.9 (6.9–6.9) 5.2 (2.8–7.4)
Disease duration 1.5 (1–4.7) 2.1 (0.9–5) 2.4 (1.8–6.1) 8.5 (8.5–8.5) 6.2 (6.2–6.2) 2.2 (1.1–5.6)
ESR 47 (13–88) 7 (3–12) 19 (7–39) 28 (28–28) 4 (4–4) 10 (5–24)*
MD VAS 
(0–10 cm)
1.5 (0–4.5) 0.5 (0–2.5) 2.3 (0–5) 6.5 (6.5–6.5) 0.5 (0.5–0.5) 1 (0–3)
No. swollen joints 0 (0–2) 0 (0–1) 0.5 (0–2) 3 (3–3) 0 (0–0) 0 (0–1)
No. joints with 
pain
0 (0–2) 0 (0–1) 0 (0–0) 2 (2–2) 0 (0–0) 0 (0–1)
No. joints with 
LOM
0 (0–0) 0 (0–1) 1 (0-2.5) 2 (2–2) 0 (0–0) 0 (0–1)
No. active joints 0 (0–2) 0 (0–1) 0.5 (0–2) 3 (3–3) 0 (0–0) 0 (0–1)
Active systemic 
features
1 (6.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
ANA status 2 (13.3%) 1 (1.4%) 0 (0%) 0 (0%) 0 (0%) 3 (2.9%)
Uveitis 0 (0%) 1 (1.4%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
PF total score 1 (0–5) 1 (0–3) 1.5 (0-8.5) 0 (0–0) 0 (0–0) 1 (0–3) 0 (0–0)#
Pain VAS 1 (0–2.5) 0 (0–2) 1 (0–3) 2.5 (2.5–2.5) 0 (0–0) 0 (0–3) 0 (0–0)#
Disease activity 
VAS
2.5 (0.5–5) 1.5 (0.5–3.5) 1.5 (1–4) 4 (4–4) 0 (0–0) 1.5 (0.5–4)
Well-being VAS 1 (0.5–4.5) 1 (0.5–3) 2 (1–4.5) 2 (2–2) 0 (0–0) 1 (0.5–3)
HRQoL PhH 1 (0–3) 1 (0–3) 2.5 (0.5–3) 1 (1–1) 0 (0–0) 1 (0–3) 0 (0–1)#
HRQoL PsH 1 (0–3) 1 (1–2) 1.5 (1–2.5) 3 (3–3) 0 (0–0) 1 (1–3) 0 (0–2)**
HRQoL Total 
Score
3 (1–4) 3 (1–5) 4 (3–5.5) 4 (4–4) 0 (0–0) 3 (1–5) 1 (0–2)#
Pain/swell. in > 1 
joint
6 (40%) 29 (42%) 6 (37.5%) 1 (100%) 0 (0%) 42 (41.2%) 3/97 (3.1%)#
Morning stiff-
ness > 15 min
2 (13.3%) 9 (13%) 4 (25%) 1 (100%) 0 (0%) 16 (15.7%) 0 (0%)#
Subjective remis-
sion
8 (53.3%) 29 (42%) 9 (56.3%) 1 (100%) 0 (0%) 47 (46.1%)
In treatment 14 (93.3%) 62 (89.9%) 16 (100%) 1 (100%) 0 (0%) 93 (91.2%)
Reporting side 
effects
3/14 (21.4%) 16/62 (25.8%) 4 (25%) 1 (100%) – 24/93 (25.8%)
Taking medication 
regularly
14/14 (100%) 55/62 (88.7%) 15/16 (93.8%) 1 (100%) – 85/93 (91.4%)
With problems 
attending school
1/6 (16.7%) 4/36 (11.1%) 1/12 (8.3%) 0 (0%) 0 (0%) 6/56 (10.7%) 0 (0%)**
Satisfied with dis-
ease outcome
2 (13.3%) 25 (36.2%) 2 (12.5%) 0 (0%) 1 (100%) 30 (29.4%)
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.96 for PF-HW, 0.88 
for PF-US. Cronbach’s alpha was 0.91 for HRQoL-PhH and 
0.71 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiophatic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 102/199 Child N = 32/133
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 89.2% 87.5%
 HRQoL PhH 62.7% 62.5%
 HRQoL PsH 86.3% 81.3%
 Pain VAS 58.8% 50.0%
 Disease activity VAS 10.8% 18.7%
 Well-being VAS 11.8% 21.9%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 3.9% 3.1%
 HRQoL PsH 1.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 93% for PF, 100% for HRQoL 80% for PF, 70% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 90% for HRQoL 100% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.83
 PF-HW 0.96 0.97
 PF-US 0.88 0.90
 HRQoL-PhH 0.91 0.84
 HRQoL-PsH 0.71 0.61
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.87 0.69
 HRQoL-PhH 0.78 0.96
 HRQoL-PsH 0.53 0.0
Spearman correlation with JIA core set variables, median
 PF 0.4 0.3
 HRQoL PhH 0.4 0.2
 HRQoL PsH 0.3 0.1
 Pain VAS 0.4 0.2
 Disease activity VAS 0.4 0.2
 Well-being VAS 0.5 0.4
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Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 6.5 days (6–7 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.87). The ICC 
for the HRQoL PhH showed a substantial reproducibility 
(ICC = 0.78), while the ICC for the HRQoL PsH showed a 
moderate reproducibility (ICC = 0.53).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.5 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.3 to 0.6 (median = 0.4), whereas PsH ranged from 
0.2 to 0.4 (median = 0.3). The PhH showed the best cor-
relation with the parent’s assessment of pain (r = 0.8, 
p < 0.001) and the PsH with the physician global assess-
ment of well-being (r = 0.4, p < 0.001). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centred and 
laboratory measures were 0.4 (0.3–0.4), 0.4 (0.4–0.5), 0.5 
(0.4–0.6), respectively.
Discussion
In this study, the Farsi version of the JAMAR was fully 
cross-culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the 
Farsi parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: 1 HRQoL item (“hav-
ing trouble getting along with other children”) showed a 
lower item’s internal consistency. However, the overall 
internal consistency was good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reliable 
proxy reporters of their disease and health status as their 
parents.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Farsi version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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